Results 161 to 170 of about 6,313 (203)

Interactions between kidney disease and diabetes: dangerous liaisons [PDF]

core   +1 more source

A novel heterozygous WFS1 variant of uncertain significance in a patient with early-onset diabetes: a case report. [PDF]

Front Endocrinol (Lausanne)
Kan W, Wang Y, Xue Y, Zhang X, Xu L.
europepmc   +1 more source

Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D). [PDF]

Pak J Med Sci
Raja UY, Wahab MU, Randhawa FA, Hussain A, Raza A, Mahar SA, Ishtiaq O, Rehman T, Qureshi FM, Ahmed I.   +9 more
europepmc   +1 more source

Once-Weekly Insulin Versus Once-Daily Insulin for Type 1 Diabetes Treatment: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. [PDF]

Endocrinol Diabetes Metab
Altobaishat O, Gadelmawla AF, Almohtasib S, Suilik HA, Manasrah A, Abouzid M, Turkmani M, Abuelazm M.   +7 more
europepmc   +1 more source

Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist. [PDF]

Diabetes Obes Metab
Horváth L, Novodvorský P, Haluzík M.
europepmc   +1 more source

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study. [PDF]

Diabetes Obes Metab
Gu W, Wu X, Zhang M, Wang X, Du Q, Kang L, Lauand F, Alvarez A, Mu Y.   +8 more
europepmc   +1 more source

Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide. [PDF]

Int J Mol Sci
Rzepiński Ł, Tywoniuk A, Jaraczewska J, Al-Shaer A, Wiciński M.   +4 more
europepmc   +1 more source

Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes. [PDF]

Diabetes Ther
Nasu R, Oura T, Ohwaki K, Imori M, Furihata K.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Degludec: A Novel Basal Insulin

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012
Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulin. Degludec, a novel basal insulin analog has the potential to overcome these
Sanjay, Kalra, Manash P, Baruah, Asfandyar K, Niazi   +2 more
openaire   +3 more sources